Get started
Author

Kaito Nihira

An inhibition of p62/ SQSTM 1 caused autophagic cell death of several human carcinoma cells
2014 · Kaito Nihira, Yasuhiro Miki, et al. · Cancer Science · 67
PDF
An activation of LC3A ‐mediated autophagy contributes to de novo and acquired resistance to EGFR tyrosine kinase inhibitors in lung adenocarcinoma
2014 · Kaito Nihira, Yasuhiro Miki, et al. · The Journal of Pathology · 52
Chimeric Mice With Humanized Livers Demonstrate Human-Specific Hepatotoxicity Caused by a Therapeutic Antibody Against TRAIL-Receptor 2/Death Receptor 5
2018 · Kaito Nihira, Ken-ichiro Nan-ya, et al. · Toxicological Sciences · 20
KK2845, a PBD dimer-containing antibody-drug conjugate targeting TIM-3-expressing AML
2025 · Jian Zou, Haruka Kinosada, et al. · Leukemia · 8
PDF
A novel mouse model of cutaneous T‐cell lymphoma revealed the combined effect of mogamulizumab with psoralen and ultraviolet a therapy
2022 · Keiko Nakahashi, Kaito Nihira, et al. · Experimental Dermatology · 4
PDF
Potent Therapeutic Activity Against Peritoneal Dissemination and Malignant Ascites by the Novel Anti-Folate Receptor Alpha Antibody KHK2805
2017 · Munetoshi Ando, Keiko Nagata, et al. · Translational Oncology · 4
PDF
Novel tetravalent bispecific antibody, PSMA/TRAIL‑R2 REGULGENT™, induces selective tumor cell apoptosis without hepatotoxicity
2025 · Makoto Nakayama, Sayaka Takagi‑maeda, et al. · Oncology Reports · 1
PDF
Non-clinical safety evaluations of next-generation therapeutic antibodies
2022 · Kaito Nihira · Folia Pharmacologica Japonica
PDF
Abstract C124: A novel anti-FOLR1 antibody developed with AccretaMab® technology, KHK2805, exhibits potent anti-cancer activity against ovarian cancer samples with the FOLR1 expression
2015 · Kaito Nihira, Munetoshi Ando, et al. · Molecular Cancer Therapeutics
Works count: 10
Citation count: 156
H-index: 4
I10-index: 3
Year
Topic
Type